Inflammatory and neurotrophic factor plasma levels are related to epilepsy independently of etiology.
Brain-Derived Neurotrophic Factor
Ciliary Neurotrophic Factor
Cytokines
/ metabolism
Epilepsy
/ etiology
Glial Cell Line-Derived Neurotrophic Factor
Humans
Inflammation
/ metabolism
Interferon-gamma
Interleukin-10
Interleukin-17
Interleukin-2
Interleukin-4
Interleukin-6
Nerve Growth Factor
Seizures
Tumor Necrosis Factor-alpha
biomarkers
cytokines
epilepsy
inflammation
neurotrophic factors
seizure frequency
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
30
06
2021
received:
26
03
2021
accepted:
15
07
2021
pubmed:
1
8
2021
medline:
19
4
2022
entrez:
31
7
2021
Statut:
ppublish
Résumé
Inflammation plays an essential role in epilepsy. Studies indicate that cytokines and neurotrophic factors can act in neuroexcitability and epileptogenesis. We aimed to investigate the association between plasma inflammatory and neurotrophic markers, seizure frequency, and chronic epilepsy subtypes. We studied 446 patients with epilepsy and 166 healthy controls. We classified patients according to etiology and seizure frequency. We measured plasma levels of interleukin-1 (IL-1), IL-2, IL-4, IL-6, IL-10, IL-17, interferon-γ (IFNγ), tumor necrosis factor α (TNFα), soluble TNF receptor 1 (sTNFr1), sTNFr2, brain-derived neurotrophic factor (BDNF), neurotrophic factor 3 (NT3), NT4/5, ciliary neurotrophic factor (CNTF), nerve growth factor (NGF), and glial cell line-derived neurotrophic factor (GDNF) by enzyme-linked immunosorbent assay or cytometric bead array. The plasma levels of BDNF, NT3, NGF, and sTNFr2 were higher, whereas IL-2, IL-4, IL-6, IL-10, IL-17, IFNγ, TNFα, CNTF, and sTNFr1 were lower in patients than controls. IL1, GDNF, and NT4/5 were similar between groups. These markers did not correlate with age, sex, and epilepsy duration. The molecule sTNFr2 was the best marker to discriminate patients from controls (area under the curve = .857), also differing between patients with frequent and infrequent seizures. This large cohort confirmed that patients with epilepsy have abnormal levels of plasma inflammatory and neurotrophic markers independent of the underlying etiology. Plasma level of sTNFr2 was related to seizure frequency and discriminated people with or without epilepsy with good accuracy, making it a potential biomarker for epilepsy and seizure burden.
Substances chimiques
Brain-Derived Neurotrophic Factor
0
Ciliary Neurotrophic Factor
0
Cytokines
0
Glial Cell Line-Derived Neurotrophic Factor
0
Interleukin-17
0
Interleukin-2
0
Interleukin-6
0
Tumor Necrosis Factor-alpha
0
Interleukin-10
130068-27-8
Interleukin-4
207137-56-2
Interferon-gamma
82115-62-6
Nerve Growth Factor
9061-61-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2385-2394Informations de copyright
© 2021 International League Against Epilepsy.
Références
Vezzani A, Balosso S, Ravizza T. Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. Nat Rev Neurol. 2019;15:459-72.
Rosa DV, Rezende VB, Costa BS, Mudado F, Schutze M, Torres KC, et al. Circulating CD4 and CD8 T cells expressing pro-inflammatory cytokines in a cohort of mesial temporal lobe epilepsy patients with hippocampal sclerosis. Epilepsy Res. 2016;20:1-6.
Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A definition and classification of status epilepticus-report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515-23.
Arisi GM. Nervous and immune systems signals and connections: cytokines in hippocampus physiology and pathology. Epilepsy Behav. 2014;38:43-7.
Abbas AK, Lichtman AH. Cellular and Molecular Immunology. 5th ed. Philadelphia: Saunders, Elsevier; 2005.
Bothwell MNGF. NGF, BDNF, NT3, and NT4. Handb Exp Pharmacol. 2014;220:3-15.
Iughetti L, Lucaccioni L, Fugetto F, Predieri B, Berardi A, Ferrari F. Brain-derived neurotrophic factor and epilepsy: a systematic review. Neuropeptides. 2018;72:23-9.
Vezzani A. Brain inflammation and seizures: evolving concepts and new findings in the last 2 decades. Epilepsy Curr. 2020;20:40S-3S.
de Vries EE, van den Munckhof B, Braun KP, van Royen-Kerkhof A, de Jager W, Jansen FE. Inflammatory mediators in human epilepsy: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2016;63:177-90.
Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:512-21.
Blumcke I, Thom M, Aronica E, Armstrong DD, Bartolomei F, Bernasconi A, et al. International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a Task Force report from the ILAE Commission on Diagnostic Methods. Epilepsia. 2013;54:1315-29.
Blumcke I, Aronica E, Urbach H, Alexopoulos A, Gonzalez-Martinez JA. A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors. Acta Neuropathol. 2014;128:39-54.
Barbosa IG, Vaz GN, Rocha NP, Machado-Vieira R, Ventura MRD, Huguet RB, et al. Plasma levels of tumor necrosis factor superfamily molecules are increased in bipolar disorder. Clin Psychopharmacol Neurosci. 2017;31(15):269-75.
Mourao AM, Vicente LCC, Abreu MNS, Vale Sant'Anna R, Vieira ELM, de Souza LC, et al. Plasma levels of brain-derived neurotrophic factor are associated with prognosis in the acute phase of ischemic stroke. J Stroke Cerebrovasc Dis. 2019;28:735-40.
Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Mahwah, NJ: Lawrence Erlbaum Associates; 1988.
Teixeira AL, de Souza RT, Zanetti MV, Brunoni AR, Busatto GF, Zarate CA, et al. Increased plasma levels of soluble TNF receptors 1 and 2 in bipolar depression and impact of lithium treatment. Hum Psychopharmacol Clin Exp. 2015;30(1):52-6.
Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244-79.
Shandra AA, Godlevsky LS, Vastyanov RS, Oleinik AA, Konovalenko VL, Rapoport EN, et al. The role of TNF-alpha in amygdala kindled rats. Neurosci Res. 2002;42:147-53.
Balosso S, Ravizza T, Aronica E, Vezzani A. The dual role of TNF-alpha and its receptors in seizures. Exp Neurol. 2013;247:267-71.
Ashhab MU, Omran A, Kong H, Gan N, He F, Peng J, et al. Expressions of tumor necrosis factor alpha and microRNA-155 in immature rat model of status epilepticus and children with mesial temporal lobe epilepsy. J Mol Neurosci. 2013;51(3):950-8.
Weinberg MS, Blake BL, McCown TJ. Opposing actions of hippocampus TNFalpha receptors on limbic seizure susceptibility. Exp Neurol. 2013;247:429-37.
Coelho FM, Narciso FM, Oliveira DM, Pereira DS, Teixeira AL, Teixeira MM, et al. sTNFR-1 is an early inflammatory marker in community versus institutionalized elderly women. Inflamm Res. 2010;59(2):129-34.
Brunoni AR, Supasitthumrong T, Teixeira AL, Vieira EL, Gattaz WF, Benseñor IM, et al. Differences in the immune-inflammatory profiles of unipolar and bipolar depression. J Affect Disord. 2020;262:8-15.
Sedger LM, McDermott MF. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants-past, present and future. Cytokine Growth Factor Rev. 2014;25:453-72.
Sinha S, Patil SA, Jayalekshmy V, Satishchandra P. Do cytokines have any role in epilepsy? Epilepsy Res. 2008;82:171-6.
Gao F, Gao Y, Zhang SJ, Zhe X, Meng FL, Qian H, et al. Alteration of plasma cytokines in patients with active epilepsy. Acta Neurol Scand. 2017;135:663-9.
Peltola J, Palmio J, Korhonen L, Suhonen J, Miettinen A, Hurme M, et al. Interleukin-6 and interleukin-1 receptor antagonist in cerebrospinal fluid from patients with recent tonic-clonic seizures. Epilepsy Res. 2000;41(3):205-11.
Mao LY, Ding J, Peng WF, Ma Y, Zhang YH, Fan W, et al. Interictal interleukin-17A levels are elevated and correlate with seizure severity of epilepsy patients. Epilepsia. 2013;54:e142-5.
Uludag IF, Duksal T, Tiftikcioglu BI, Zorlu Y, Ozkaya F, Kirkali G. IL-1beta, IL-6 and IL1Ra levels in temporal lobe epilepsy. Seizure. 2015;26:22-5.
Nowak M, Bauer S, Haag A, Cepok S, Todorova-Rudolph A, Tackenberg B, et al. Interictal alterations of cytokines and leukocytes in patients with active epilepsy. Brain Behav Immun. 2011;25:423-8.
Uludag IF, Bilgin S, Zorlu Y, Tuna G, Kirkali G. Interleukin-6, interleukin-1 beta and interleukin-1 receptor antagonist levels in epileptic seizures. Seizure. 2013;22:457-61.
Bauer S, Cepok S, Todorova-Rudolph A, Nowak M, Koller M, Lorenz R, et al. Etiology and site of temporal lobe epilepsy influence postictal cytokine release. Epilepsy Res. 2009;86:82-8.
Lehtimäki KA, Keränen T, Palmio J, Keränen R, Hurme M, Honkaniemi J, et al. Increased plasma levels of cytokines after seizures in localization-related epilepsy. Acta Neurol Scand. 2007;116:226-30.
Vieira ELM, de Oliveira GNM, Lessa JMK, Goncalves AP, Oliveira ACP, Bauer ME, et al. Peripheral leukocyte profile in people with temporal lobe epilepsy reflects the associated proinflammatory state. Brain Behav Immun. 2016;53:123-30.
Vieira EL, de Oliveira GN, Lessa JM, Goncalves AP, Sander JW, Cendes F, et al. Interleukin-1beta plasma levels are associated with depression in temporal lobe epilepsy. Epilepsy Behav. 2015;53:131-4.
Strauss KI, Elisevich KV. Brain region and epilepsy-associated differences in inflammatory mediator levels in medically refractory mesial temporal lobe epilepsy. J Neuroinflammation. 2016;13(13):270.
Guo W, Zheng DH, Sun FJ, Yang JY, Zang ZL, Liu SY, et al. Expression and cellular distribution of the interleukin 2 signaling system in cortical lesions from patients with focal cortical dysplasia. J Neuropathol Exp Neurol. 2014;73:206-22.
He JJ, Li S, Shu HF, Yu SX, Liu SY, Yin Q, et al. The interleukin 17 system in cortical lesions in focal cortical dysplasias. J Neuropathol Exp Neurol. 2013;72:152-63.
Bramham CR, Messaoudi E. BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog Neurobiol. 2005;76:99-125.
Kandratavicius L, Monteiro MR, Assirati JA Jr, Carlotti CG Jr, Hallak JE, Leite JP. Neurotrophins in mesial temporal lobe epilepsy with and without psychiatric comorbidities. J Neuropathol Exp Neurol. 2013;72:1029-42.
Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther. 2013;138:155-75.
Berry A, Bindocci E, Alleva E. NGF, brain and behavioral plasticity. Neural Plast. 2012;2012:784040.
Ullal GR, Michalski B, Xu B, Racine RJ, Fahnestock M. NT-3 modulates BDNF and proBDNF levels in naive and kindled rat hippocampus. Neurochem Int. 2007;50:866-71.
Binder DK, Croll SD, Gall CM, Scharfman HE. BDNF and epilepsy: too much of a good thing? Trends Neurosci. 2001;24:47-53.
Shetty AK, Zaman V, Shetty GA. Hippocampal neurotrophin levels in a kainate model of temporal lobe epilepsy: a lack of correlation between brain-derived neurotrophic factor content and progression of aberrant dentate mossy fiber sprouting. J Neurochem. 2003;87:147-59.
Hong Z, Li W, Qu B, Zou X, Chen J, Sander JW, et al. Serum brain-derived neurotrophic factor levels in epilepsy. Eur J Neurol. 2014;21:57-64.
LaFrance WC Jr, Leaver K, Stopa EG, Papandonatos GD, Blum AS. Decreased serum BDNF levels in patients with epileptic and psychogenic nonepileptic seizures. Neurology. 2010;5(75):1285-91.
Chen NC, Chuang YC, Huang CW, Lui CC, Lee CC, Hsu SW, et al. Interictal serum brain-derived neurotrophic factor level reflects white matter integrity, epilepsy severity, and cognitive dysfunction in chronic temporal lobe epilepsy. Epilepsy Behav. 2016;59:147-54.
Schmidt-Kastner R, Humpel C, Wetmore C, Olson L. Cellular hybridization for BDNF, trkB, and NGF mRNAs and BDNF-immunoreactivity in rat forebrain after pilocarpine-induced status epilepticus. Exp Brain Res. 1996;107:331-47.
He XP, Butler L, Liu X, McNamara JO. The tyrosine receptor kinase B ligand, neurotrophin-4, is not required for either epileptogenesis or tyrosine receptor kinase B activation in the kindling model. Neuroscience. 2006;11(141):515-20.
Kanter-Schlifke I, Georgievska B, Kirik D, Kokaia M. Seizure suppression by GDNF gene therapy in animal models of epilepsy. Mol Ther. 2007;15:1106-13.
Duveau V, Fritschy JM. PSA-NCAM-dependent GDNF signaling limits neurodegeneration and epileptogenesis in temporal lobe epilepsy. Eur J Neuorsci. 2010;32:89-98.
Kahn MA, Ellison JA, Speight GJ, de Vellis J. CNTF regulation of astrogliosis and the activation of microglia in the developing rat central nervous system. Brain Res. 1995;10(685):55-67.
Gerlach J, Donkels C, Munzner G, Haas CA. Persistent gliosis interferes with neurogenesis in organotypic hippocampal slice cultures. Front Cell Neurosci. 2016;10:131.